Open AccessReactivation of p53 in cells expressing hepatitis B virus X‐protein involves p53 phosphorylation and a reduction of Hdm2
Author(s) -
Wang JinHee,
Yun Chawon,
Kim Sujeong,
Chae Sunyoung,
Lee Young Ik,
Kim WookHwan,
Lee JaeHo,
Kim Wankee,
Cho Hyeseong
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00754.x
Subject(s) - hbx , phosphorylation , doxorubicin , biology , cancer research , kinase , cancer cell , nuclear protein , cytoplasm , microbiology and biotechnology , virus , cancer , hepatitis b virus , biochemistry , virology , transcription factor , gene , genetics , chemotherapy
Multifunctional activities of the hepatitis B virus X‐protein (HBx) in cells have been largely implicated in the development of liver cancer; one of these activities is the loss of p53 function by sequestering p53 in the cytoplasm. We have previously found that doxorubicin increased the p53 levels in cells containing p53‐binding HBx protein and restored the p53‐mediated transcriptional activity that was suppressed by HBx. Here, we investigated the mechanism underlying p53 reactivation. We found that six phosphorylation sites of the Serine residues of p53 were efficiently phosphorylated in HBx‐expressing ChangX‐34 cells, suggesting that the binding of HBx to the p53 protein does not interfere with the phosphorylation of p53 by signaling kinases. In addition, doxorubicin caused a dramatic reduction of Hdm2 mRNA and protein levels in cells expressing HBx. Intriguingly, reactivation of p53 was accompanied with a nuclear accumulation of p53 and the phosphorylated p53 at Serine15 was only detected in nuclear fraction, but not in cytosolic fraction of doxorubicin‐treated ChangX‐34 cells. Functional restoration of the p53 protein in HBx‐expressing cells occurs according to the dual effects of doxorubicin: a significant reduction of Hdm2 expression and a nuclear accumulation of the phosphorylated p53 protein. Thus, proper usage of doxorubicin as an effective antitumor agent may be reevaluated and can be extended to tumors primarily caused by infection of DNA tumor viruses. ( Cancer Sci 2008; 99: 888–893)